Another non-unanimous PNAS retraction, for potential anti-cancer drug, after company’s method proves unreliable
There’s another non-unanimous retraction in the Proceedings of the National Academy of Sciences (PNAS) this week, and this one involves an anti-tumor antibody that may not be what the authors originally thought it was. According to the notice for “The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility:”